So we had a couple approvals for ET patients this year, and ropeginterferon was one of them. It’s a pegylated interferon alpha that has been studied in two studies in patients with essential thrombocythemia following its previous approval on polycythemia vera patients. One of them was EXCEED-ET and one of them was SURPASS-ET. So the approval was based on both of these studies and actually has a pretty broad label used in patients with essential thrombocythemia in the need for therapy...
So we had a couple approvals for ET patients this year, and ropeginterferon was one of them. It’s a pegylated interferon alpha that has been studied in two studies in patients with essential thrombocythemia following its previous approval on polycythemia vera patients. One of them was EXCEED-ET and one of them was SURPASS-ET. So the approval was based on both of these studies and actually has a pretty broad label used in patients with essential thrombocythemia in the need for therapy. That includes frontline or second-line therapies as well as patients that would be high risk or historically low risk. And that came from the design of the studies where SURPASS-ET was a second-line study. There was primarily enrolling patients in the Asian region, less of Native Americans or Canadians, and then basically had a comparator arm anagrelide. So it was Phase III randomized where patients previously failed and exposed to hydroxyurea or any frontline would be eligible to enroll. And then ropeg interferon showed sustained improvements in responses where primary endpoints was durable, complete hematologic response, and lack of progression of splenomegaly symptoms. So that was achieved on ropeg in about 43% of patients and in 6% of patients on anagrelide. And that followed study that was named EXCEED-ET That actually did include only North American region patients and not patients with a single-arm ropeg interferon with the same schedule. That study included patients refractory to hydroxyurea, so second line, similarly to previous trial, but also patients that would be a low risk or patients that need therapy, but not having a standard definitions of high risk. So that means that supporting the approval across the broad patients with ET that need treatments, which is kind of nice for the landscape because we are often missing on patients that would not be historically high risk, but had a therapy needs because of the symptoms, splenomegaly, and control counts. And that is actually a matter of fitting the landscape. So the advice for the clinical practitioner would be, actually, ropeg interferon has consistently showed superior efficacy over second-line therapy. So definitely, if patients fail front-line therapies, ropeginterferon, if not contraindicated, should be suggested and considered for any patient population. They don’t have a clear contraindication. And then also for a specifically young population where ropeginterferon has been historically used, and also patients that actually want to do more than just controlling the blood counts, because obviously ropeg interferon is also some other agents rolling in a space, have a better ability to control the disease itself, meaning we have seen molecular responses even that early, as in 12 months above of the SURPASS-ET and EXCEED-ET study, that it was achieving about one-third of the patient. That’s remarkable mark saying that the study had such a short follow-up. So a follow-up will come up with a longer time. That’s the most important for decision-making for using it frontline or lower risk patients. However, there are already some data from other population, especially PV. So just watching up on the space to see how the agent evolves and kind of more paying attention and learning how to use the agent because it’s a subcutaneous version of therapy, not orals. And it comes with some side effect profile that has to be monitored and watched for.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.